UK advises under-40s to take alternative to AstraZeneca COVID-19 shot | Inquirer News

UK advises under-40s to take alternative to AstraZeneca COVID-19 shot

/ 06:54 PM May 07, 2021

A dose of the AstraZeneca COVID-19 vaccine is prepared in a vaccination centre at Newmarket Racecourse, amid the coronavirus disease outbreak in Newmarket, Britain March 26, 2021

FILE PHOTO: A dose of the AstraZeneca COVID-19 vaccine is prepared in a vaccination centre at Newmarket Racecourse, amid the coronavirus disease outbreak in Newmarket, Britain March 26, 2021. REUTERS/Andrew Couldridge/File Photo

LONDON — Britain’s panel of vaccine advisers on Friday said that people under 40 should be offered an alternative to Oxford/AstraZeneca’s COVID-19 shot where possible, due to a small risk from rare blood clots.

The Joint Committee on Vaccination and Immunization (JCVI) broadened the age range of people who should be offered alternatives to include people aged 30-39. Previously, advice was only for people under 30 to be offered an alternative vaccine.

Article continues after this advertisement

AstraZeneca’s COVID-19 shot, developed by Oxford, has resulted in reports of rare blood clots with low platelet levels that occur more commonly in younger adults, with several countries advising the shot is given only to older people.

FEATURED STORIES

The JCVI said that the advice reflected low levels of COVID-19 infection in Britain and the availability of other vaccines made by Pfizer and Moderna.

“As COVID-19 rates continue to come under control, we are advising that adults aged 18–39 years with no underlying health conditions are offered an alternative to the Oxford/AstraZeneca vaccine, if available and if it does not cause delays in having the vaccine,” said Wei Shen Lim, COVID-19 Chair for JCVI.

Article continues after this advertisement

“The advice is specific to circumstances in the UK at this time and maximises use of the wide portfolio of vaccines available.”

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: AstraZeneca

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.